Apellis Pharmaceuticals, Inc. 4

Nur Nicholson, CTO of Apellis Pharmaceuticals, had all 116,338 directly held common shares and all outstanding RSUs and stock options cashed out or cancelled for cash and contingent value rights in connection with Biogen’s May 14, 2026 acquisition of Apellis, leaving no remaining Apellis equity holdings.

On May 14, 2026, Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, Inc., reported the cash‑out and cancellation of all equity holdings in connection with the closing of Biogen Inc.’s acquisition of Apellis. A total of 116,338 shares of Apellis common stock previously held directly were converted into the right to receive $41.00 per share in cash plus one contingent value right (CVR) per share, with potential additional payments up to $4.00 per share upon milestone achievement, leaving Nicholson with no direct share ownership post‑merger. In addition, multiple restricted stock unit awards covering 22,610, 45,220, 24,284 and 41,250 shares, as well as other RSU tranches, were automatically cancelled and converted into cash‑and‑CVR-based contingent rights under the Merger Agreement, subject generally to continued service and the original vesting schedules but no longer subject to performance conditions. Separately, several outstanding stock options with exercise prices ranging from $19.39 to $66.30 were terminated: in‑the‑money options (those below $41.00) were cashed out for the spread over $41.00 plus CVRs, options between $41.00 and below $45.00 were converted into CVRs only (with milestone payments adjusted for any excess strike over $41.00), and options at or above $45.00 were cancelled without consideration. As a result of the merger consideration structure, Nicholson’s economic interest shifted entirely from Apellis equity securities to cash and contingent value rights, with no remaining reportable common stock or options.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224604

Alert Tier

5